Ori secures $120M commercial cell therapy manufacturing accord
News from Fierce Pharma: Ori secures $120M commercial cell therapy manufacturing accord
Ori Biotech
Private
Ori Biotech is a London and Philadelphia-based manufacturing technology company whose IRO platform automates cell and gene therapy production end to end; the company received an FDA Advanced Manufacturing Technology (AMT) Designation and dosed its first clinical patient in 2025.
Company Info
Sector:Equipment & Machines
Headquarters:London, United Kingdom; Philadelphia, Pennsylvania, United States
Founded:2015
Website:oribiotech.com/
Funding Round:Series B
Total Funding:~$281M raised to date
Funding & Investor Relations
Notable Investors
- Amadeus Capital Partners
- Octopus Ventures
- Kindred Capital
Upcoming Milestones & Key Dates
2026-09
Partnership
10-year, $120M partnership announced to advance automated manufacturing for commercial cell therapies
2026
Partnership milestone
Switch of a commercial cell therapy onto the IRO platform for an undisclosed pharma partner
Recent News
Leadership Team
Jason C. Foster, MBA
Chief Executive Officer and Executive Director
Chris Mason
Co-Founder
Farlan Veraitch
Co-Founder